These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33538758)

  • 41. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
    Roetker NS; Peng Y; Ashfaq A; Gilbertson DT; Wetmore JB
    Am J Nephrol; 2019; 49(3):225-232. PubMed ID: 30820015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease.
    Meza K; Biswas S; Zhu YS; Gajjar A; Perelstein E; Kumar J; Akchurin O
    Pediatr Nephrol; 2021 Jun; 36(6):1579-1587. PubMed ID: 33387018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients.
    Jeong S; Oh JM; Oh KH; Kim IW
    PLoS One; 2017; 12(2):e0170535. PubMed ID: 28152049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
    Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
    Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.
    Okoye JU; Arodiwe EB; Ulasi II; Ijoma CK; Onodugo OD
    Afr Health Sci; 2015 Sep; 15(3):941-8. PubMed ID: 26957985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of CKD-MBD phenotype on health-related quality of life in patients receiving maintenance hemodialysis: A cross-sectional study.
    Luo L; Chen Q
    J Int Med Res; 2020 Feb; 48(2):300060519895844. PubMed ID: 32054360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
    Zhang C; Wen J; Li Z; Fan J
    BMC Nephrol; 2013 Oct; 14():226. PubMed ID: 24134531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
    Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M
    Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study.
    Molina P; Molina MD; Pallardó LM; Torralba J; Escudero V; Álvarez L; Peris A; Sánchez-Pérez P; González-Rico M; Puchades MJ; Fernández-Nájera JE; Giménez-Civera E; D'Marco L; Carrero JJ; Górriz JL
    J Nephrol; 2021 Aug; 34(4):1189-1199. PubMed ID: 33394344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
    Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
    Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study.
    Magagnoli L; Cozzolino M; Caskey FJ; Evans M; Torino C; Porto G; Szymczak M; Krajewska M; Drechsler C; Stenvinkel P; Pippias M; Dekker FW; de Rooij ENM; Wanner C; Chesnaye NC; Jager KJ;
    Nephrol Dial Transplant; 2023 Oct; 38(11):2562-2575. PubMed ID: 37230954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study.
    Ghosh B; Brojen T; Banerjee S; Singh N; Singh S; Sharma OP; Prakash J
    Indian J Nephrol; 2012 Jul; 22(4):285-91. PubMed ID: 23162273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
    Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT
    Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
    Uhlig K; Berns JS; Kestenbaum B; Kumar R; Leonard MB; Martin KJ; Sprague SM; Goldfarb S
    Am J Kidney Dis; 2010 May; 55(5):773-99. PubMed ID: 20363541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.
    Gršković A; Ćelić T; Španjol J; Markić D; Devčić B; Bobinac D; Rački S
    Acta Clin Croat; 2023 Jul; 62(Suppl2):46-52. PubMed ID: 38966016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
    Navarro JF; Mora C; Macia M; Garcia J
    Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
    Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
    Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
    Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.